...
首页> 外文期刊>Health Economics Review >Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs
【24h】

Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

机译:停止使用固定剂量的抗逆转录病毒药物(FDC)与继续使用FDC的HIV治疗和与药物相关的不良事件的成本分析

获取原文
           

摘要

Background The lower sales price of generic lamivudine has caused healthcare administrators to consider abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative is to administer the individual components of the FDCs separately, thus incorporating the new generic lamivudine medication. Methods The Balearic Islands Health Service ordered the discontinuation of the treatment with FDCs in July 2010, but FDCs were reintroduced in August 2010. At that point, an independent, retrospective cost analysis was performed by Son Llàtzer Hospital. A total of 75 patients who were treated from July to August 2010 underwent replacement of their FDC treatment with the individual components. Additionally, 150 patients who continued using FDCs were randomly selected. For both patient groups, the antiretroviral therapy that was administered and the costs associated with management of adverse events were recorded. The study period used for the cost calculations was the average number of days that patients used separate components of FDCs (120 days). An alternative analysis was performed to consider the costs of the extra follow-up visit (consultation and clinical tests) that was required for patients who changed their antiretroviral therapy. Results Considering antiretroviral therapies and adverse events, the administration of the separate components increased the total daily cost by 0.72 € per patient compared to treatment with FDCs. When the cost of an extra follow-up visit was considered, the daily cost increased by 3.61 € per patient. Conclusions Our study suggests that the discontinuation of FDC treatment and the replacement with the administration of separate antiretroviral agents could lead to an increase in healthcare costs due to the higher rate of adverse events that was observed with the discontinuation of FDCs.
机译:背景普通拉米夫定的较低销售价格已导致医疗保健管理者考虑取消包含拉米夫定和恩曲他滨的固定剂量抗逆转录病毒药物组合(FDC)。替代方法是分别管理FDC的各个组成部分,从而合并新的通用拉米夫定药物。方法巴利阿里群岛卫生服务局于2010年7月下令终止使用FDC的治疗,但于2010年8月重新引入FDC。那时,Son Lltztzer医院进行了独立的回顾性成本分析。从2010年7月至2010年8月,共有75例患者接受了FDC的单独治疗。此外,随机选择了150名继续使用FDC的患者。对于两个患者组,均记录了所施用的抗逆转录病毒疗法以及与不良事件管理相关的费用。用于成本计算的研究期是患者使用FDC的单独组件的平均天数(120天)。进行了替代分析,以考虑改变抗逆转录病毒疗法的患者所需的额外随访(咨询和临床测试)的费用。结果考虑到抗逆转录病毒疗法和不良事件,与使用FDC进行治疗相比,单独使用这些成分会使每位患者的每日总费用增加0.72€。考虑额外的随访费用后,每位患者的每日费用增加了3.61欧元。结论我们的研究表明,终止FDC治疗并用单独的抗逆转录病毒药物替代可能会导致医疗费用增加,因为终止FDC引起的不良事件发生率更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号